ISTO Technologies, Inc. To Present At 2nd Annual Jefferies & Company, Inc. Healthcare Conference
Jun 4, 2008
St. Louis, MO – ISTO Technologies, Inc., a privately held orthobiologic company, announced today that it will participate in the 2nd Annual Jefferies & Company, Inc. Healthcare Conference in New York, NY from June 24-26, 2008. Mitchell Seyedin, Ph. D., President and CEO of ISTO, will present on Thursday, June 26th at 9:00 a.m. Eastern Time. The conference will showcase a diverse group of companies and industry experts in the areas of biotechnology, CROs, healthcare facilities & services, healthcare IT services, medical devices & diagnostics, pharmaceutical services and specialty pharmaceuticals.
ISTO, an orthobiologic company, is focused on developing breakthrough products to regenerate and restore damaged cartilage and bone for sports medicine and spinal therapy indications. Cartilage regeneration is often called the “holy grail” of the orthopedic industry because of its potential to restore function to damaged joints that otherwise have limited healing potential. Cartilage serves as a “shock absorber” protecting all joints, including spinal discs, from the wear and tear experienced during motion. ISTO’s innovative products are designed to address very large markets with unmet clinical needs.
The Company’s leading cartilage product is DeNovo® ET, a laboratory-grown engineered cartilage tissue grown from juvenile chondrocytes using ISTO’s cell-based platform technology. DeNovo ET is a scaffold-free living cartilage designed to repair and restore joint function in the knee. The surgeries and primary endpoints of the Phase I/II human clinical trials are nearing completion and the data collection process is currently underway.
ISTO’s development pipeline also includes NuQu™, a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc. Degeneration of disc cartilage begins in the nucleus and is accompanied by cell death and tissue destruction. NuQu has been developed for use in conjunction with a minimally invasive, non-surgical, outpatient procedure.
ISTO’s third major program is InQu®, an osteobiologic bone graft extender for spinal applications, which was launched as a commercial product in March 2008. InQu is a differentiated biomaterial scaffold of synthetic and biologic polymers. It is designed to facilitate the growth of host repair responses in any tissue to which it is implanted. ISTO’s hybrid scaffold represents a new class of biomaterials that combine the best properties of synthetic polymers and biological materials to create a product with superior structure and biological activity over currently available scaffold implants. InQu is a product with great biology, shape, form and controlled resorption rate.
ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com or contact Scott Gill, Chief Financial Officer, at 314-995-6049.